
AG Prof. Dr. med. Lars Bullinger
We study the genomic, epigenomic and transcriptomic changes associated with hematological malignancies, with a strong focus on acute myeloid leukemia (AML).
Sie befinden sich hier:
Focus of research
Our lab is committed to unravelling the genomic, epigenomic and transcriptomic changes leading up to and driving acute myeloid leukemia (AML) and other hematological malignancies. To this end, we employ massively parallelized next-generation sequencing (NGS) technologies, from Illumina and Oxford nanopore, to compare patient-derived primary tumor and matched control samples. Data analysis is developed and performed in-house by our own small team of bioinformaticians; findings of interest are followed up by functional validation in the lab. With close ties to the clinic, we are thus able to connect bench and bedside with our research in a dynamic exchange between dry in-silico and hands-on wet lab work. We are also well connected internationally and, for example, heavily involved in large cooperative projects such as SyTASC, SYNtherapy, and HARMONY.
News and announcements
Selected publications
- Hirsch, S., Blätte, T. J., Grasedieck, S., Cocciardi, S., Rouhi, A., Jongen-Lavrencic, M., … Bullinger, L. (2017). Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia. Haematologica, 102(12), 2039–2047. doi:10.3324/haematol.2017.172866 PubMed
- Blätte, T. J., Schmalbrock, L. K., Skambraks, S., Lux, S., Cocciardi, S., Dolnik, A., … Bullinger, L. (2019). getITD for FLT3-ITD-based MRD monitoring in AML. Leukemia. doi:10.1038/s41375-019-0483-z PubMed
- Cocciardi, S., Dolnik, A., Kapp-Schwoerer, S., Rücker, F. G., Lux, S., Blätte, T. J., … Döhner, K. (2019). Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nature Communications, 10(1). doi:10.1038/s41467-019-09745-2 PubMed
- Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., … Campbell, P. J. (2016). Genomic Classification and Prognosis in Acute Myeloid Leukemia. New England Journal of Medicine, 374(23), 2209–2221. doi:10.1056/nejmoa1516192 PubMed